The Technical Analyst
Forte Biosciences, Inc. [FBRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Forte Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.21% $0.671
America/New_York / 1 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 24.45 mill |
| EPS: | -1.000 |
| P/E: | -0.670 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 36.44 mill |
| Avg Daily Volume: | 0.0348 mill |
| RATING 2024-05-01 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.670 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.670 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.379 (-43.54%) $-0.292 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.615 - 0.727 ( +/- 8.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Riley Antony A | Buy | 9 375 | Common Stock |
| 2024-04-01 | Riley Antony A | Sell | 3 345 | Common Stock |
| 2024-04-01 | Riley Antony A | Sell | 9 375 | Restricted Stock Units |
| 2024-04-01 | Wagner Paul A. | Buy | 31 250 | Common Stock |
| 2024-04-01 | Wagner Paul A. | Sell | 2 453 | Common Stock |
| INSIDER POWER |
|---|
| 86.82 |
| Last 94 transactions |
| Buy: 4 603 379 | Sell: 363 400 |
Forecast:
16:00 - $0.684
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.684
Forecast 2: 16:00 - $0.684
Forecast 3: 16:00 - $0.684
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.671 (-8.21% ) |
| Volume | 0.0329 mill |
| Avg. Vol. | 0.0348 mill |
| % of Avg. Vol | 94.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FBRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FBRX
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Latest Press Releases
2024-03-18 16:05:00 - Press Release
Forte Biosciences, Inc. Announces 2023 Results And Provides Business Update
Dallas--(business wire)--forte biosciences, inc. (www.fortebiorx.com) (nasdaq: fbrx), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 business highlights “forte achieved a major milestone by advancing fb-102 into the clinic and beating the timelines we targeted in our third quarter business update. the single ascending dose (sad) portion of the fb-102 phase 1 trial was success.
2023-12-01 16:01:00 - Press Release
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Dallas--(business wire)--forte biosciences, inc. (www.fortebiorx.com) (nasdaq: fbrx), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the nasdaq stock market rules. in accordance with nasdaq listing rule 5635(c)(4), the compensation committee of forte's board of directors approved the grant of an equity award to purchase 25,000 shares of common stock to a new non-executive employee as a material inducement to s.
2023-09-14 10:50:00 - Press Release
Iss And Glass Lewis Recommend Forte Biosciences Stockholders Vote For Boardroom Change At The Company's Upcoming Annual Meeting
New york--(business wire)--camac partners, llc (“camac”) and atg capital management, llc (“atg”) (together with the other participants in their solicitation, the “concerned stockholders,” the “group” or “we”), which collectively own approximately 8.5% of the outstanding common stock of forte biosciences, inc. (nasdaq: fbrx) (“forte” or the “company”), today announced that leading independent proxy advisory firms institutional shareholder services inc. (“iss”) and glass, lewis & co., llc (“g.
2023-09-06 15:15:00 - Press Release
Concerned Stockholders Of Forte Biosciences And Its Independent Director Candidates Share Key Facts That Reinforce The Need For Urgent Change In The Company's Boardroom
New york--(business wire)--camac partners, llc (“camac”) and atg capital management, llc (“atg”) (together with the other participants in their solicitation, the “concerned stockholders,” the “group” or “we”) collectively own approximately 8.5% of the outstanding common stock of forte biosciences, inc. (nasdaq: fbrx) (“forte” or the “company”). today, the group and its independent director candidates – michael hacke and chris mcintyre – responded to misrepresentations and distortions included i.
2023-08-25 08:00:00 - Press Release
Concerned Stockholders Of Forte Biosciences File Definitive Proxy Statement And Send Letter To Stockholders
New york--(business wire)--camac partners, llc (“camac”) and atg capital management, llc (“atg”) (together with the other participants in their solicitation, the “concerned stockholders,” the “group” or “we”), who collectively own approximately 8.5% of the outstanding common stock of forte biosciences, inc. (nasdaq: fbrx) (“forte” or the “company”), today announced that they have filed a definitive proxy statement with the u.s. securities and exchange commission (the “sec”) in connection with f.
Latest News
2024-03-25 13:01:09 - Zacks Investment Research
What Makes Forte Biosciences (FBRX) a New Buy Stock
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2021-10-06 18:42:00 - Seeking Alpha
BiomX: Undervalued With Multiple Upcoming Catalysts
2021-09-06 12:42:00 - Newsfile Corp
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or "the Company") (NASDAQ: FBRX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Forte announced after the market closed on September 2, 2021,...
2021-09-04 20:47:15 - Pulse2
FBRX Stock: 82.3% Decrease Explanation
The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.
2021-09-03 19:42:00 - Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.
2021-09-03 18:19:23 - Zacks Investment Research
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
2021-09-03 14:31:09 - Benzinga
Why Forte Biosciences Stock Is Down Over 80% Today
Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are appreciative of the clinical trial sites and the patients for participating in this trial and we are grateful to our investors for taking the risk to support the advancement of a new therapeutic modality for atopic dermatitis,” said Paul Wagner, CEO of Forte Biosciences.
2021-09-03 14:14:00 - PRNewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).
2021-09-03 11:21:53 - The Motley Fool
Why Forte Biosciences Stock Is Imploding Today
The company announced dismal results from a phase 2 study of its only pipeline candidate.
2021-09-03 07:21:02 - Market Watch
Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment
Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its lead product candidate FB-401, a treatment for atopic dermatitis. Trading volume spiked to 2.8 million shares ahead of the open, compared with the full-day average of about 754,000 shares.